Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Peripheral ablation of type III adenylyl cyclase induces hyperalgesia and eliminates KOR-mediated analgesia in mice
Wen-Wen Zhang, Hong Cao, Yang Li, Xian-Jun Fu, Yu-Qiu Zhang
Wen-Wen Zhang, Hong Cao, Yang Li, Xian-Jun Fu, Yu-Qiu Zhang
View: Text | PDF
Research Article Neuroscience

Peripheral ablation of type III adenylyl cyclase induces hyperalgesia and eliminates KOR-mediated analgesia in mice

  • Text
  • PDF
Abstract

Ca2+/calmodulin-stimulated group I adenylyl cyclase (AC) isoforms AC1 and AC8 have been involved in nociceptive processing and morphine responses. However, whether AC3, another member of group I ACs, is involved in nociceptive transmission and regulates opioid receptor signaling remains elusive. Here, we report that conditional KO of AC3 (AC3 CKO) in L3 and L4 DRGs robustly facilitated the mouse nociceptive responses, decreased voltage-gated potassium (Kv) channel currents, and increased neuronal excitability. Furthermore, we report AC3 CKO eliminated the analgesic effect of κ-opioid receptor (KOR) agonist and its inhibition on Kv channel by classical Gαi/o signaling or nonclassical direct interaction of KOR and AC3 proteins. Interestingly, significantly upregulated AC1 level and cAMP concentration were detected in AC3-deficient DRGs. Inhibition of AC1 completely reversed cAMP upregulation, neuronal excitability enhancement, and nociceptive behavioral hypersensitivity in AC3-CKO mice. Our findings suggest a crucial role of peripheral AC3 in nociceptive modulation and KOR opioid analgesia.

Authors

Wen-Wen Zhang, Hong Cao, Yang Li, Xian-Jun Fu, Yu-Qiu Zhang

×

Figure 6

Inhibition of AC1 reversed the enhanced neuronal excitability and decreased Kv currents in AC3-deleted DRG neurons.

Options: View larger image (or click on image) Download as PowerPoint
Inhibition of AC1 reversed the enhanced neuronal excitability and decrea...
(A–C) Bath application of AC1 specific inhibitor NB001 (50 μM) for 30 minutes. AC3-CKO–induced attenuation of rheobase required to evoke AP (A) and RMP (more hyperpolarization (B) were reversed in DRG neurons. The membrane capacitance had no difference of recorded neurons (C). *P < 0.05; 1-way ANOVA followed by post hoc Dunnett’s multiple-comparison test; n = 25 (Ctrl-Veh, CKO-NB001) and 26 (Ctrl-NB001, CKO-Veh, cells). (D) Examples of AP traces from control and AC3-CKO DRG neurons with vehicle (Veh) or NB001 application. (E) NB001 reduced the increased number of APs evoked by current injection in AC3 deleted DRG neurons. *P < 0.05, **P < 0.01, CKO-Veh versus Ctrl-Veh; #P < 0.05, ##P < 0.01, ###P < 0.001, CKO-NB001 versus CKO-Veh; 2-way RM ANOVA followed by Bonferroni’s test; n = 25 (Ctrl-Veh, CKO-NB001) and 26 (Ctrl-NB001, CKO-Veh, cells). (F and G) NB001 significantly increased IA (F) and slightly increased IK (G) densities in AC3-deleted DRG neurons. *P < 0.05, ***P < 0.001; 2-way RM ANOVA followed by Bonferroni’s test; n = 16 (Ctrl-Veh, Ctrl-NB001, CKO-NB001) and 22 (CKO-Veh, cells).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts